# AK119

Source: https://onco.cc/drugs/ak119/  
OnCo record `ak119` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AK119 is an experimental monoclonal antibody from Akeso in phase 2 trials for colorectal cancer, aimed at CD73 / adenosine axis.

## Summary

AK119 is a monoclonal antibody developed by Akeso. Its target is CD73 / adenosine axis (the sponsor names CD73). The sponsor states: AK119 is an anti-CD73 monoclonal antibody, studied in combination with AK112 for advanced solid tumours and colorectal cancer. ClinicalTrials.gov describes the intervention as: AK119 is an anti-CD73 monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in colorectal cancer. The largest, NCT05846867, plans to enrol 170 participants with primary completion was scheduled for 2026-05-08 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: AK119 is an anti-CD73 monoclonal antibody, studied in combination with AK112 for advanced solid tumours and colorectal cancer.

## Sources

- ClinicalTrials.gov: trials of AK119: https://clinicaltrials.gov/search?intr=AK119

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/)
- companies: [Akeso](https://onco.cc/companies/akeso/)
- trials: [A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer](https://onco.cc/trials/nct05846867/), [Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05689853/)

---
JSON: https://onco.cc/api/v1/entities/ak119.json